Risk factors and prevention of vascular complications in polycythemia vera

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 5, 1997, Pages 455-461

  Barbui, Tiziano ^a   Finazzi, Guido ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Polycythemia vera; Prevention; Risk factors; Thrombosis

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; ANTICOAGULANT AGENT;

AGE; ARTICLE; CANCER RISK; HUMAN; LEUKOCYTOSIS; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RISK FACTOR; SECOND CANCER; THROMBOCYTE DYSFUNCTION; THROMBOCYTOSIS; THROMBOSIS; VASCULAR DISEASE;

EID: 0030727717     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996122     Document Type: Article

References (43)

1. Gruppo Italiano Studio Policitemia (GISP): Polycythemia vera: The natural history of 1213 patients followed over 20 years. Ann Intern Med 123:656-664, 1995.
2. Pearson TC, G Wetherley-Mein: Vascular occlusive episodes and venous hematocrit in primary proliferative polycythaemia. Lancet 2:1219-1222, 1978
3. Hoffman R, L Wasserman: Natural history and management of polycythemia vera. Adv Intern Med 24:255-285, 1979.
4. Schaler AI. Bleeding and thrombosis in myeloproliferative disorders. Blood 64:1-12, 1984.
5. Rozman C, M Giralt, E Feliu, et al: Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67:2658-2663, 1991.
6. Pearson TC, PRD Humprey, DJ Thomas, et al: Hematocrit, blood viscosity, cerebral blood flow and vascular occlusion. In: Lowe GDO, JC Barhenel, CD Forbes (eds): Clinical Aspects of Blood Viscoty and Cell Deformability. Springer, Berlin, 1981, pp 97-107.
7. Thomas DJ, GH du Boulay, J Marshall, et al: Cerebral blood flow in polycythaemia. Lancet 2:161-163, 1977.
8. Thomas DJ, GH du Boulay, J Marshall, et al: Effect of haematocrit on cerebral blood-flow in man. Lancet 2:941-943, 1977.
9. Messinezy M, TO Nunan, TC Pearson: Brain perfusion in polycythemia using 99TcmHMPAO: Effect of treatment. Eur J Haematol 51:120-121, 1993.
10. Lowe GDO, AJ Lee, A Rumley, et al: Blood viscosity and risk of cardiovascular events: The Edinburgh Artery Study. Br J Haematol 96:168-173, 1997.
11. Landolfi R, B Rocca, C Patrono: Bleeding and thrombosis in myeloproliferative disorders: Mechanisms and treatment. Crit Rev Oncol Haematol 20:203-222, 1995.
12. Berk PD, JD Goldberg, PB Donovan, et al: Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 23:132-143, 1986.
13. Kessler CM, HG Klein, RJ Havlik: Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Haematol 50:157-167, 1982.
14. Michiels JJ, J Abels, J Steketee, et al: Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 102:466-471, 1985.
15. Grossi A, S Rossetti, A Vannucchi, et al: Occurrence of haemorrhagic and thrombotic events in myeloproliferative disorders: A retrospective study of 108 patients. Clin Lab Haematol 10:167-175, 1988.
16. Cortelazzo S, G Finazzi, M Ruggeri, et al: Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: A prospective randomized trial. N Engl J Med 332:1132-1136, 1995.
17. Pearson TC, T Barbui: The management of polycythemia vera. Hematology 2:55-64, 1997
18. Finazzi G, U Budde, JJ Michiels: Bleeding time and platelet function in myeloproliferalive disorders. Leukemia Lymphoma 22(suppl 1):71-78, 1996.
19. Schafer AI: Essential thrombocythemia. Prog Hemostas Thromb 10:69-96, 1991.
20. van Genderen PJJ, H Leenknegt, JJ Michiels, et al: Acquired von-Willebrand disease in myeloproliferative disorders. Leukemia Lymphoma 22(suppl 1):79-82, 1996.
21. Ernst E, DE Hammerschmidt, U Bagge, et al: Leukocytes and the risk of ischemic diseases. JAMA 257:2318-2324, 1987.
22. Romson JL, BG Hook, SL Kunkel: Reduction of the extent of ischemic myocardial injury by neutrophil depletion in dog. Circulation 67:1016-1023, 1983.
23. Semeraro N, P Montemurro, MR Rossiello, et al: Involvement of leukocytes in haemostasis and thrombosis. In: Barbui T, S Cortelazzo, P Viero, S Gorini, G deGaetano (eds.): Cellular Blood Components in Haemostasis and Thrombosis Libbey, Paris, 1988, pp 81-95.
24. de Gaetano G, V Evangelista, G Rajtar, et al: Activated polymorphonuclear leukocytes stimulate platelet function. Thromb Res (suppl IX):25-32, 1990.
25. Rambaldi A, K Masuhara, GM Borleri, et al: Flow cytometry of leukocyte alkaline phosphatase in normal and pathologic haemopoietic cells. Br J Haematol 96:815-822, 1997.
26. Najean Y, P Mugnier, C Dresch, et al: Polycythaemia vera in young people: An analysis of 58 cases diagnosed before 40 years. Br J Haematol 67:285-291, 1987.
27. Mitus AJ, T Barbui, LN Shulman, et al: Hemostatic complications in young patients with essential thrombocythemia. Am J Med 88:371-375, 1990.
28. Cortelazzo S, P Viero, G Finazzi, et al: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556-562, 1990.
29. Berk PD, LR Wasserman, SM Fruchtman, et al: Treatment of polycythemia vera: A summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, PD Berk, NI Berlin (eds): Polycythemia Vera and the Myeloproliferative Disorders. Saunders, Philadelphia, 1995, pp 166-194.
30. Najean Y, C Dresch, JD Rain: The very long course of polycythemia: A complement to the previously published data of the Polycythemia Vera Study Group. Br J Haematol 86:233-235, 1994.
31. 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood 89:2319-2327, 1997.
32. Bilgrami S, BR Greenberg: Polycythemia rubra vera. Semin Oncol 22:307-326, 1995.
33. Hoffman R, S Boswell: Polycythemia vera. In: Hoffman R, EJ Benz, SJ Shattil, B Furie, HJ Cohen, LE Silberstein (eds): Hematology. Basic Principles and Practice, (ed 2). Churchill Livingstone, Edinburgh, 1995, pp 834-853.
34. Barbui T: Treatment of polycythemia vera. Br J Haematol Special Issue: Meet the Expert Session of the Second AHA:57-60, 1996.
35. Marchioli R, R Landolfi, T Barbui, et al: Feasibility of randomized trials in rare diseases: The case of polycythemia vera. Leukemia Lymphoma 22(suppl 1):121-128, 1996.
36. Fruchtman SM, K Mack, ME Kaplan, et al: From efficacy to safety: A Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 34:17-23, 1997.
37. Tatarsky I, R Sharon: Management of polycythemia vera with hydroxyurea. Semin Hematol 34:24-28, 1997.
38. Silver RT: Interferon alfa: Effects of long-term treatment for polycythemia vera. Semin Hematol 34:40-50, 1997.
39. Petitt RM, MN Silverstein, ME Petrone: Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 34:51-54, 1997.
40. Tartaglia AP, JD Goldberg, PD Berk, et al: Adverse effects of anti-aggregating platelet therapy in the treatment of polycythemia vera. Semin Hemalol 23:172-176, 1986.
41. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy - I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81-106, 1994.
42. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy - III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophlaxis among surgical and medical patients. Br Med J 308:235-246, 1994.
43. Gruppo Italiano Studio Policitemia (GISP): Low-dose aspirin in polycythaemia vera: A pilot study. Br J Haematol 97:453-456 1997.